C Heading

Summary

Affiliation: University Hospital Aintree
Country: UK

Publications

  1. ncbi request reprint Conus peptides and neuroprotection
    Christine E Heading
    Department of Biological Sciences, The Open University, Milton Keynes, UK
    Curr Opin Investig Drugs 3:915-20. 2002
  2. ncbi request reprint Ziconotide (Elan Pharmaceuticals)
    C E Heading
    IDrugs 4:339-50. 2001
  3. ncbi request reprint TA-CD. Xenova
    Christine E Heading
    Department of Biological Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA, UK
    IDrugs 5:1070-4. 2002
  4. ncbi request reprint Common ground in therapy of substance abuse
    C E Heading
    Faculty of Science, The Open University, Parsifal College, 527 Finchley Road, London, NW3 7BG
    IDrugs 4:1266-74. 2001
  5. ncbi request reprint Siramesine H Lundbeck
    C Heading
    Curr Opin Investig Drugs 2:266-70. 2001
  6. ncbi request reprint Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction
    Christine E Heading
    The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 8:71-7. 2007
  7. ncbi request reprint Vivitrex (Alkermes/Cephalon)
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 7:81-8. 2006
  8. ncbi request reprint Conus toxins: targets and properties
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA UK
    IDrugs 7:1011-6. 2004
  9. ncbi request reprint NicVAX (Nabi Biopharmaceuticals)
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK
    IDrugs 6:1178-81. 2003
  10. ncbi request reprint Recent advances against substance abuse
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA, UK
    IDrugs 6:681-7. 2003

Detail Information

Publications11

  1. ncbi request reprint Conus peptides and neuroprotection
    Christine E Heading
    Department of Biological Sciences, The Open University, Milton Keynes, UK
    Curr Opin Investig Drugs 3:915-20. 2002
    ..The poor pharmacokinetic profile of the peptides remains a challenge...
  2. ncbi request reprint Ziconotide (Elan Pharmaceuticals)
    C E Heading
    IDrugs 4:339-50. 2001
    ..This included patients who had failed morphine therapy, or who had become intolerant of therapy due to side-effects. The drug was safe and well tolerated over periods as long as 3 years [351606]...
  3. ncbi request reprint TA-CD. Xenova
    Christine E Heading
    Department of Biological Sciences, The Open University, Walton Hall, Milton Keynes, MK7 6AA, UK
    IDrugs 5:1070-4. 2002
    ..It was renamed TA-CD when ownership was transferred to Cantab [463510], [463511]. By April 2002, a second phase IIa dose escalation trial was underway [445298], which was ongoing in September 2002 [463866]...
  4. ncbi request reprint Common ground in therapy of substance abuse
    C E Heading
    Faculty of Science, The Open University, Parsifal College, 527 Finchley Road, London, NW3 7BG
    IDrugs 4:1266-74. 2001
    ..A simple working framework for classifying approaches to drug development is suggested, and four distinct pharmacological approaches applicable both to established and potential products are identified...
  5. ncbi request reprint Siramesine H Lundbeck
    C Heading
    Curr Opin Investig Drugs 2:266-70. 2001
    ..Phase III trials are expected to take place in 2002 [387270]. A series of compounds have been synthesized by Lundbeck, the most potent of which may serve as a backup compound [179036]...
  6. ncbi request reprint Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction
    Christine E Heading
    The Open University in the North, Faculty of Science, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 8:71-7. 2007
    ..A phase II trial was initiated in Switzerland in January 2005 and in February 2006, Cytos Biotechnology announced that it planned to begin a phase IIb/III trial in 2007...
  7. ncbi request reprint Vivitrex (Alkermes/Cephalon)
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House, Regent Centre, Gosforth, Newcastle upon Tyne NE3 3PW, UK
    Curr Opin Investig Drugs 7:81-8. 2006
    ..Alkermes and Cephalon are currently awaiting Food and Drug Administration review of the Vivitrex new drug application, which was granted Priority Review in May 2005...
  8. ncbi request reprint Conus toxins: targets and properties
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA UK
    IDrugs 7:1011-6. 2004
    ..In turn, this presents problems of bioavailability, while the potency is a potential source of toxicity...
  9. ncbi request reprint NicVAX (Nabi Biopharmaceuticals)
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes MK7 6AA, UK
    IDrugs 6:1178-81. 2003
    ..Nabi Biopharmaceuticals is developing NicVAX, a proprietary vaccine designed as a potential therapeutic to prevent and treat nicotine addiction...
  10. ncbi request reprint Recent advances against substance abuse
    Christine E Heading
    The Open University, Department of Biological Sciences, Walton Hall, Milton Keynes, MK7 6AA, UK
    IDrugs 6:681-7. 2003
    ..For cocaine abuse, the main focus is on products targeting the dopamine reuptake system...
  11. ncbi request reprint Gender issues and the pharmacotherapy of substance abuse
    Christine E Heading
    Faculty of Science, The Open University in the North, Eldon House Regent Centre, Gosforth, Newcastle upon Tyne, NE3 3PW, UK
    IDrugs 11:428-32. 2008
    ..Some gender differences will have more clinical significance than others, but any difference related to gender has the potential to complicate clinical trials and other studies...